Boston Medical Center
Boston, Massachusetts, 02118, United States
NCT Number: NCT00576394
entGlycemic control has been found to improve clinical outcomes following Coronary Bypass Surgery. This study tests the hypothesis that obtaining tighter glycemic control(80-120mg/dl) as opposed to more moderate control (120-180mg/dl) will further improve outcomes.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Phase 1
Boston, Massachusetts, 02118, United States
150 diabetic patients will be randomized to achieve aggressive glycemic control (80-120mg/dl) vs moderate control (120-180mg/dl) using intravenous insulin infusions beginning at anesthetic induction and continuing for 18 hours following surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
IV insulin drip to keep serum glucose between 80-120mg/dl.
Time frame: 24 hours following surgery
Time frame: 24 hours following surgery
American Heart Association
Other
Impact of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes Following Coronary Artery Bypass Graft Surgery in Diabetic Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06178874
Critical Illness, Disease Attributes
Cairo, Egypt
View Trial DetailsNCT06217679
Glucose Metabolism Disorders, Glycemic Control
Waterloo, Ontario, Canada
View Trial DetailsNCT07686939
Glucose Metabolism Disorders, Glycemic Control
Taizhou, Zhejiang, China
View Trial DetailsNCT07513961
Diabetes Mellitus, Diabetes Mellitus, Type 2
Alanya, Antalya, Turkey (Türkiye)
View Trial Details